
- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2 million shares, closed regular trading session at $90.20.
- Synlogic (NASDAQ:SYBX) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate SYNB1353 for the potential treatment of homocystinuria (HCU). Synlogic shares traded as high as 6.06 percent, in a range of $0.93 to $1.05 on day volume of 871.25 thousand shares versus three months average volume of 141.7 thousand shares, closed regular trading session at $1.01.